Development of novel bispecific antibody to enhance therapeutic effect of T cells against EGFR-expressing triple negative breast cancer
碩士 === 臺北醫學大學 === 臨床藥物基因體學暨蛋白質體學碩士學位學程 === 107
Main Authors: | Yi-Ting Lee, 李依庭 |
---|---|
Other Authors: | Kuo-Hsiang Chuang |
Format: | Others |
Language: | zh-TW |
Published: |
2019
|
Online Access: | http://ndltd.ncl.edu.tw/handle/cd3wbb |
Similar Items
-
A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective Against Triple Negative Breast Cancer Via Multiple Mechanisms of Action
by: Nishant Mohan, et al.
Published: (2021-03-01) -
A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
by: Joanie Del Bano, et al.
Published: (2019-07-01) -
Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
by: Jason J. Zoeller, et al.
Published: (2020-11-01) -
Targeting EGFR in Triple Negative Breast Cancer
by: Naoto T. Ueno, Dongwei Zhang
Published: (2011-01-01) -
Balancing Efficacy and Selectivity of Bispecific c-METxEGFR Antibodies
by: Sellmann, Carolin
Published: (2016)